BIIB vs PATH · P/E 21, rev $9.89B vs P/E 19, rev $1.61B
Biogen Inc (BIIB) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BIIB and PATH stock pages for the full models.
Not investment advice.